Merck & Co. stock heads into the open after a 1.0 percent drop
Published on 09/09/2026 at 07:34 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Merck & Co. stock closed at about USD 148 on the NYSE on September 8, 2026, slipping roughly 1.0 percent from the previous session in a day of moderate selling. Compared with its recent levels near the upper end of its 52-week range, the shares now sit a few percent below the latest high, reflecting some cooling after a strong run.
September 8, 2026 in numbers
Merck & Co., Inc. (ISIN US58933Y1055, NYSE: MRK) ended the September 8, 2026 session around USD 148 on the NYSE, down about USD 1.5 or 1.0 percent from the prior close, according to NYSE quote data. Intraday, market data indicate the stock traded between an approximate high in the USD 150 area and a low closer to USD 147, leaving the close nearer to the lower half of the day’s range. Trading volume reached more than 11 million shares, above the recent average and signaling brisk activity as the price eased.
Per NYSE data, the S&P 500 benchmark index also weakened slightly on September 8, 2026, closing modestly lower in percent terms, so Merck & Co. shares underperformed the broader market on the day. A number of recent market wraps have pointed out that Merck’s stock has been trading near its 52-week high, with a prior close of USD 150.33 on September 4, 2026 leaving it only about 4 percent below a 52-week peak around USD 156.92 reached in late August, as reported by Yahoo Finance.
On September 8, 2026, analyst activity provided a notable backdrop for the session. The Fly reported that Guggenheim raised its price target on Merck from USD 146 to USD 170 while reiterating a buy rating, citing higher sales estimates for oncology assets following positive data. A similar headline on September 8, 2026 from Benzinga highlighted the same move, underscoring continued constructive analyst sentiment even as the share price edged lower in the latest session.
Today’s outlook for September 9, 2026
Looking to today, Merck & Co. has investor relations activity on the calendar. As Yahoo Finance reported on September 8, 2026, Merck is scheduled to participate in the Morgan Stanley 24th Annual Global Healthcare Conference, giving management an opportunity to update institutional investors on strategy and key pipeline items; any new commentary from that appearance could influence sentiment around the stock in the coming sessions. Broader healthcare sector performance and moves in the S&P 500 today may also shape how Merck & Co. shares trade once the US market opens, given the stock’s recent tendency to track major indices while reacting to drug development and analyst news.
